Remedium Lifecare Ltd

For the year ending March 2025, Remedium Life reported an operating income of 405.25 crore and a net profit after tax of 2.13 crore, with an EPS of 0.04. The company faced an operating loss of 1.09 crore before other income and had total liabilities of 1,720.31 crore.

Remedium Lifecare's latest Q2 FY26 results show a net profit increase of 85.38% to ₹8.62 crores, but a 2.04% decline in net sales raises concerns about sustainability, especially given significant year-on-year declines in both sales and profit. Overall, while there are some positive signs, the company's financial health remains precarious.

Remedium Life reported an operating income of 405.25 Cr and a slight operating loss of 1.09 Cr for the year ending March 2025, resulting in a profit after tax of 2.13 Cr and an EPS of 0.04. Despite total liabilities and assets both at 1,720.31 Cr, the company faced significant negative cash flow from operations at -1,134.00 Cr, offset by a positive cash flow from financing activities.

As of 04-Nov, Remedium Lifecare Ltd's stock price is 1.59, up 6.0% today and outperforming its sector. Despite a recent short-term recovery, the stock has declined significantly year-to-date and over the past year, while the broader market is experiencing downward pressure.

As of 24-Sep, Remedium Lifecare Ltd's stock price is at 1.50, with no change. Despite recent short-term gains, the company faces significant financial challenges, including high debt, consecutive quarterly losses, and a year-to-date decline of -58.03%, indicating a bleak long-term outlook.

As of 23-Sep, Remedium Lifecare Ltd's stock price is at 1.50, down 3.23%, with a year-to-date decline of 58.03%. The stock has underperformed its sector and the broader market, indicating weak investor participation and mixed momentum.

As of 22-Sep, Remedium Lifecare Ltd's stock price is 1.55, up 1.97% recently, but it faces significant challenges with a high Debt to EBITDA ratio and a history of losses. While it has outperformed the Sensex in the short term, it has a year-to-date decline of -56.63%, indicating substantial long-term risks.

As of 19-Sep, Remedium Lifecare Ltd's stock price is 1.52, up 1.33% today, but it has declined 76.31% over the past year, indicating significant long-term challenges despite a recent short-term gain of 16.03%. The company faces high debt levels and declining sales, raising concerns about its financial health and investor interest.

As of 18-Sep, Remedium Lifecare Ltd is priced at 1.50, with no change and a significant decline of -76.44% over the past year, indicating ongoing financial struggles despite a slight increase in delivery volume. The company's poor performance relative to the market and negative financial metrics suggest a challenging outlook for investors.

As of 17-Sep, Remedium Lifecare Ltd's stock price is 1.50, down 0.66%. The stock has significantly underperformed the market, with a year-to-date decline of 58.03% and negative financial results contributing to poor investor sentiment.

As of 15-Sep, Remedium Lifecare Ltd's stock price is at 1.52, unchanged, with short-term gains of 5.56% over the past week but a significant year-to-date decline of 57.47%. The company faces serious financial challenges, including a high Debt to EBITDA ratio and a drastic decline in net sales, raising concerns about its long-term viability.

As of 12-Sep, Remedium Lifecare Ltd's stock price is at 1.52, unchanged, but has outperformed its sector today. Despite recent short-term gains, the company's significant losses and poor financial health indicate a bleak long-term outlook.

As of 11-Sep, Remedium Lifecare Ltd's stock price is at 1.52, up 2.7%, but faces significant challenges with a high Debt to EBITDA ratio and a 76.36% decline in net sales, indicating poor long-term growth potential. Despite recent short-term gains, the stock has underperformed over the past year, highlighting volatility and financial risks.

As of 10-Sep, Remedium Lifecare Ltd's stock price is 1.48, up 2.78%, with strong short-term performance but significant long-term challenges, including a 58.59% year-to-date decline and poor financial health indicators. Despite recent gains, the company's sustainability and recovery prospects appear risky.

As of 09-Sep, Remedium Lifecare Ltd's stock price is at 1.44, unchanged, with recent short-term gains but significant long-term declines of -59.71% year-to-date and -79.43% over the past year, alongside poor financial performance and declining investor confidence.

As of 08-Sep, Remedium Lifecare Ltd's stock price is at 1.44, with a recent short-term gain of 3.60%. However, the company faces significant challenges, including a high Debt to EBITDA ratio and negative performance over the last year, indicating a risky investment despite short-term improvements.

As of 05-Sep, Remedium Lifecare Ltd's stock price is 1.44, up 9.09% recently, but faces significant challenges with a high Debt to EBITDA ratio and declining net sales, leading to a poor long-term growth outlook. Despite short-term gains, the stock has underperformed over the past year, indicating volatility and financial risks.

As of 04-Sep, Remedium Lifecare Ltd's stock price is at 1.32, up 3.13% today, but the company faces significant financial challenges, including high debt levels and consecutive quarterly losses, leading to a negative long-term outlook despite recent short-term gains.